## Introduction

- Many protein drugs try to selectively engage certain cell populations
    + IL-2
    + BMP
    + Antibodies
    + CAR-T cells
    + ADCs
- Strategies
    + Affinity
    + Valency [@doi:10.1038/srep40098]
    + Combinations [@pmid:28886385]
    + Bispecifics [@pmid:30145356]
- Heterogeneity is a key barrier to specific drugs
- Cell therapies tried synthetic logic gates, but difficult as therapy
    + Not off the shelf
    + Safety concerns
    + Cost
    + Manufacturing difficulty, including reliability
- Intro to paper

